ACTRIMS 2023 | Serum biomarkers of brain atrophy in MS

Multiple sclerosis (MS) progression is complex and measured mostly with qualitative clinical and radiographic evaluations. Ferhan Qureshi, VP – Biomarker Product Development, Octave, Menlo Park, CA, shares findings from a study seeking to evaluate disease progression from a biological perspective using serum proteins. The study sought to identify serum biomarkers associated with radiographic indicators of progression independent of relapse activity (PIRA) using well-characterized longitudinal cohorts with and without severe progression. In total, almost 3000 proteins were analyzed. GFAP and NfL were also measured by Simoa assays and the Octave Custom Assay Panel and were used as benchmarks to evaluate associations relative to growth gray and white matter volume. Results showed that more than 60 proteins measured at baseline had prognostic potential to predict atrophy in the gray or white matter as significant or greater than NfL or GFAP. Future work includes validation in independent cohorts and multivariate approaches to more accurately predict brain atrophy. This interview took place at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2023 in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.